Roche’s BTK inhibitor, fenebrutinib, cuts relapse rates in patients with relapsing multiple sclerosis (RMS), but safety ...
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American ...
The oral BTK inhibitor race in RMS is now a two-horse affair, with fenebrutinib vying against Novartis' remibrutinib, already ...
One of the DJB officials said that bids for all three packages have been invited and the process will be wrapped up by the end of May ...
The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...
Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis (RMS) trials, revealing that deaths from ...
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to ...
Mapi Pharma’s GA Depot was associated with stable disability scores over time in people with both RMS and PPMS, data show.
These results underscore that fenebrutinib has potential as a high-efficacy oral treatment for RMS. Its unique mode of action may offer a differentiated profile by targeting dual drivers of MS within ...
By Marleen Kaesebier and Patricia Weiss ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was ...
Motorola Solutions (NYSE: MSI) today announced CommandCentral RMS, a comprehensive records and case management solution designed to accelerate reporting and case closures by consolidating a public ...
TG Therapeutics completes enrollment in a phase III study of subcutaneous Briumvi for treating RMS in adults, with data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results